SGLT-2 inhibitors significantly lower risk of Atrial Fibrillation: Study Dr Satabdi Saha4 Feb 2021 9:45 AM ISTA recent review published in Diabetes, Obesity & Metabolism and based on a clinical trial suggests that there is a significantly lower risk of...
Empagliflozin Improves Heart Failure with rEF in Nondiabetic patients: Study MD Bureau31 Jan 2021 3:18 PM ISTIn patients with type 2 diabetes, sodium-glucose cotransporter 2 inhibitors (SGLT2i) reduce the risk of hospitalization for heart failure by 30% to...
SGLT2 inhibitors may trigger rare complications for COVID-19 patients Hina Zahid30 Dec 2020 11:15 AM ISTDiabetes is a known risk factor for morbidity and mortality related to COVID-19. In diabetes patients, rare but severe complications, like the...
Canagliflozin has kidney-protective effects in patients with advanced kidney disease Dr Kartikeya Kohli20 Nov 2020 10:57 PM ISTWashington, DC - Researchers have found in Subgroup Analysis of the Randomized CREDENCE Trial, that the diabetes drug canagliflozin slowed kidney...
Drug combo controls blood sugar, weight and BP in Diabetics: Study Dr. Kamal Kant Kohli3 Nov 2020 12:00 PM ISTPHILADELPHIA - Researchers at Thomas Jefferson University have found in a new multi-center double-blind, phase 3, randomized controlled trial that ...
ESC update: Empagliflozin Cuts risk of Hospitalization, CV Mortality in HFrEF: EMPEROR Hina Zahid29 Aug 2020 11:45 AM ISTSophia Antipolis, France - Empagliflozin is second SGLT2 inhibitor after dapagliflozin to show a significant benefit in the treatment of reduced...
Diabetes drug canagliflozin associated with amputation risk in older adults: BMJ Medha Baranwal26 Aug 2020 6:42 PM IST USA: The increased amputation risk associated with the use of the diabetes drug canagliflozin is small and most obvious in older adults having...
Empagliflozin add on to insulin premix effectively lowers blood sugar in diabetes: Study Medha Baranwal25 Aug 2020 7:09 PM ISTTaiwan: The addition of SGLT2 inhibitor empagliflozin versus linagliptin for 24 weeks to premixed insulin provides better blood sugar...
SGLT2 inhibitors may increase risk of genital mycotic infections, finds review Medha Baranwal22 Aug 2020 10:30 AM ISTUSA: Researchers have found in a review that the use of SGLT2 inhibitors increases the risk of mild genital mycotic infections (GMIs). Due to which...
No increased risk of Knee Amputations with SGLT2 Inhibitors, finds study Dr Satabdi Saha17 Aug 2020 2:26 PM ISTA recent study has reported no association between SGLT2 inhibitor use and incident below-knee amputations among patients with type 2 diabetes when...
Rosuvastatin coprescription with canagliflozin tied to Statin toxicity Hina Zahid4 Aug 2020 12:30 PM ISTResearchers have found in a case study that Coprescription of rosuvastatin and canagliflozin may lead to Statin toxicity.Physicians should be aware...
Ertugliflozin reduces hospitalization risk due to heart failure in diabetes Medha Baranwal25 Jun 2020 10:45 AM ISTDelhi: SGTL2 inhibitor ertugliflozin reduces heart failure hospitalization risk but does not confer a cardiovascular mortality benefit in...
